Ann: Trading Halt, page-26

If it is Medgate, which would seem the most likely, it will be interesting to see how Medgate will roll this out across other countries that they operate, including the Philippines, India and the UAE.

It looks like the AI assisted triage tool, which assist in identifying if a patient should be directed to the ResAppDx test, is being rolled out to the Philippines this year (https://www.bworldonline.com/medgate-to-roll-out-ai-assisted-teleconsultation/)

Some interesting stats are mentioned in this article. Medgate are receiving 10,000 calls per day in Switzerland and 500 per day in the Philippines. It shows how much more advanced and mature the telehealth market is in Europe.

Based on these numbers, with respiratory conditions making up between 33%-50% of all telehealth consultations and using the sliding scale of $5-$10 per test, gives a revenue range of $4.29m-$13.00m per year.

Most importantly, the value of this deal is not in the quantum of dollars it will bring in, but

• the experience that this would have given the team in understanding the telehealth clinical workflows from an advanced and established player like Medgate player, and
• real world clinical validation of ResAppDx within that clinical workflow

Any likely deals in the pipeline with other telehealth players should surface shortly and the time to integrate ResAppDx clinically and technically should only be a fraction of the time it has taken to get Medgate onboard.